In this phase I project, the Offeror proposes to use his novel proprietary platform to discover high-affinity, highly specific, rabbit monoclonal antibodies (mAbs) against a panel of six bat immune markers. Once the mAb clones are produced and characterized, the Offeror will use them to develop sandwich ELISA assays for cytokines and flow cytometry assays for cytokine receptors for investigators to detect the expression of these bat antigens in primary bat cells or samples. If successful, these reagents will help us better understand the immune responses of bats after viral infections and support a NIAID research priority.